VOLITIONRX LTD (VNRX)
US9286611077 - Common Stock
VOLITIONRX LTD
NYSEARCA:VNRX (12/18/2024, 10:38:38 AM)
0.6328
+0.04 (+7.25%)
Company Profile
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. The company is headquartered in Henderson, Nevada and currently employs 110 full-time employees. The company went IPO on 2015-02-06. The firm is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Company Info
VOLITIONRX LTD
1489 West Warm Springs Road, Suite 110
Henderson NEVADA 78738
P: 16466501351
CEO: Cameron Reynolds
Employees: 101
Website: https://volition.com/
VNRX News
8 days ago - ChartmillWhich stocks are moving after the closing bell on Tuesday?As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
2 months ago - Market News VideoTuesday Sector Leaders: Waste Management, Diagnostics3 months ago - Virtual Investor ConferencesLife Sciences Virtual Investor Forum Agenda Announced for September 19thCompany Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
4 months ago - InvestorPlaceVNRX Stock Earnings: VolitionRX Beats EPS, Misses Revenue for Q2 2024VNRX stock results show that VolitionRX beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
6 months ago - ACCESSWIRENexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV7 months ago - InvestorPlaceVNRX Stock Earnings: VolitionRX Beats EPS, Misses Revenue for Q1 2024VNRX stock results show that VolitionRX beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
VNRX Twits
Here you can normally see the latest stock twits on VNRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
